REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES
|
|
- Ross Barker
- 5 years ago
- Views:
Transcription
1 REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES Author: Lenita Wannmacher Application: To perform a quick review of medroxyprogesterone acetate tablet in order to decide on its deletion from the 14 th Edition of the WHO Model List of Essential Medicines. The question is whether there is an urgent case for deletion or whether a fuller systematic review is required. Background In 2004, WHO Pharmaceuticals Newsletter 1 reported a Pfizer Canada advice originated by results of new clinical studies that suggest the association between use of medroxyprogesterone acetate suspension for injection and substantial loss in bone mineral density. The publication stressed: The loss in bone density is greater with increasing duration of treatment. The loss in bone density may not be completely reversible. In women of all ages, careful re-evaluation of the risks and benefits of treatment should be carried out in those who wish to continue use for more than two years. In women with significant lifestyle and/or medical risk factors for osteoporosis, other methods of contraception should be considered. Long-term use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with a reduction in bone mineral density (BMD), particularly in the lumbar spine. The cause of DMPA-associated bone loss is not known, but the relative estrogen deficiency induced by DMPA use could be responsible. Actually, in the 13 th WHO Model List of Essential Medicines (section 18.7 Progestogens) a medroxyprogesterone acetate tablet was included. It seems that oral use of MPA (commonly associated to estrogens) could have a different consequence in bone metabolism. Aims of the search: To review the contemporary clinical uses of medroxyprogesterone acetate with evidenced efficacy. To assess the available literature in order to evaluate negative pharmacological effects of oral and injectable formulations on bone mineral density, as well as evaluate clinical outcomes such as fractures. Thus, to weigh the potential medical benefits versus its potential risks. Methods: A Medline search ( medroxyprogesterone bone effects ) for systematic reviews and randomised controlled trials (RCTs), from 2000 to 2005, yielded no meta-analyses and 36 RCTs. Most of them analysed surrogate endpoints (bone mineral density) or presented secondary analyses (for instance from WHI, HERS and PEPI studies), some associated with MPA injection, other ones with estrogen and progestogen combination for RHT. 1
2 Comments Uses and benefits Medroxyprogesterone acetate (MPA) is a C21 steroid with selective activity very similar to that of progesterone itself. Oral MPA was widely used with estrogens for postmenopausal hormone replacement until this combination therapy had evidenced more risks than benefits (WHI study). Even though progestogens alone are still used for treating menopausal symptoms (hot flushes). Four RCTs found that progestogens alone reduced vasomotor symptoms compared with placebo and one RCT found no significant difference in vasomotor symptoms between progestogens and placebo. One RCT found no significant difference in vasomotor symptoms between progesterone alone and oestrogen alone. There are no RCTs examining effects of progestogens alone on urogenital symptoms 2. The depot form of medroxyprogesterone injection is used as a long-acting progestogen only contraceptive (administered intramuscularly, a 150mg dose provides effective contraception for three months. Other clinical indications are secondary amenorrhoea, uterine bleeding disorders, luteal-phase support to treat infertility, and premature labour. Additionally, MPA have been used as a palliative treatment for metastatic endometrial carcinoma and renal carcinoma. More recent studies evidencing some benefits A RCT 3 compared a high-dose oral MPA (1 g for 9 months) with tamoxifen as adjuvant hormone therapy for early-stage breast cancer. The relapse-free survival rate at 7 years in the tamoxifen arm was 93%, versus 81% in the MPA arm (P = 0.02). Another study 4 examined the effect of an oral MPA therapy in 12 HIV-infected patients under appropriate nutrition for anabolism, concluding that MPA might improve the efficacy of an oral protein-rich nutritional support in HIV-infected patients. A Japanese randomized controlled study 5 evaluated the efficacy of add-backed therapy by every-other-day administration of mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) on GnRH agonists (GnRH-a) treatment in Japanese women with symptomatic endometriosis. At the end of treatment, the frequency of genital bleeding revealed no significant differences between the two groups. The add-back group could prevent the loss of bone density. Another study 6 compared oral MPA with tamoxifen as an adjuvant hormonal therapy for two years in the early stages of endometrial cancer. After a median follow-up period of 56 months (range months), no differences in the disease-free and overall survival rates were observed with both medicines. Side effects were more frequent and severe in the MPA-group than in the tamoxifen group. In the 16,608 postmenopausal women participating in WHI trial, who were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus MPA (2.5 mg per day orally) or placebo, the potential benefits in colorectal cancer were determined by blinded central adjudication. There were 43 invasive colorectal cancers in the hormone group and 72 in the placebo group (hazard ratio: 0.56; 95%CI= ; P=0.003). Then, relatively short-term use 2
3 of estrogen plus progestin was associated with a decreased risk of colorectal cancer 7. Potential risks (or benefits?) on calcium metabolism MPA INJECTION A randomised clinical trial 8 compared the effect of depot medroxyprogesterone acetate (DMPA) and two types of oral contraceptives (OC) on bone mineral density (BMD) among women years of age with those not using hormonal contraception (controls). Users of DMPA experienced a mean BMD loss of 2.74% over 12 months compared with controls who sustained a 0.37% loss (P = 0.01). Users of OCs generally demonstrated a gain. Observed changes in BMD among DMPA users differed from women who used either type of pill (P < 0.002). So, DMPA has an adverse effect on BMD, in comparison with OCs or nonhormonal methods, when used for 12 months. The same group of investigators performed a new study 9 with similar design, but longer. A comparison among MPA injection use, oral contraception (pills) and nonhormonal contraception (controls) measured their effect on bone mineral density after 24 months. Women using DMPA for 24 months experienced, on average, a 5.7% loss in bone mineral density, with a 3.2% loss occurring between months 12 and 24. Bonferroni-adjusted pairwise comparisons demonstrated that bone mineral density changes from baseline to 24 months among DMPA users differed significantly from changes experienced by either of the pill groups or the control group. So, loss of bone mineral density associated with DMPA use appears to be linear during the first 2 years of use. A randomized, double-blind controlled trial 10 undertaken in 38 premenopausal women with a minimum 2 year DMPA use allocated the participants to receive conjugated estrogens (0.625 mg/d orally) and a matching placebo. All continued with regular DMPA injections throughout the study (2 years). In the estrogentreated group, mean lumbar spine BMD increased 1%, whereas in the placebo group it fell 2.6%, over 2 years. These data support the view that the likely cause of DMPA-associated bone loss is estrogen deficiency and demonstrate that it can be arrested by estrogen replacement therapy. MPA TABLETS A prospective, randomized, double-blind, placebo-controlled, crossover trial 11 compared the effectiveness of administering MPA (20 mg/d orally) in either the first (protocol A) or last (protocol B) 12-week period as well as a 6-month course of leuprolide acetate (1 mg/d, SC) on calcium (Ca) metabolism. Estimated Ca balance decreased significantly during GnRH-a treatment alone. The addition of MPA attenuated the decrease in estimated Ca balance. Another study 12 evaluated the effects of low-dose continuous combined conjugated estrogens and MPA on several parameters, including bone density in postmenopausal women. Low-dose continuous combined hormone replacement therapy can provide an effective protection against the activation of bone turnover and osteoporosis. One study 13 was undertaken in 2,763 postmenopausal women enrolled for the study HERS to determine if estrogen plus progestin reduces the incidence of 3
4 fractures. Women were randomly assigned to either mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1,380) or placebo (n = 1,383). During 10,554 person years of follow-up, 286 women experienced a fracture: 138 in the treatment group (26.3 per 1,000 person years) and 148 in the placebo group (28.0 per 1,000 person years) [HR= 0.94; 95%CI: ; P = 0.61). There was no evidence of a reduction in the incidence of fractures in older women not selected for osteoporosis. In the Women's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment had fewer fractures. To test the hypothesis that the relative risk reduction of estrogen plus progestin on fractures differs according to risk factors for fractures, a randomized controlled trial 14 was performed in postmenopausal women (WHI participants). Women were randomly assigned to receive conjugated equine estrogen, mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin group and 896 women (11.1%) in the placebo group experienced a fracture (HR= 0.76; 95%CI: ). This study demonstrates that estrogen plus progestin increases BMD and reduces the risk of fracture in healthy postmenopausal women. A double-blind, randomized, placebo-controlled study 15 was conducted over 3 years, to determine whether the positive effects of hormone/estrogen replacement therapy (H/ERT) on postcranial bone density are accompanied by similar positive effects on oral bone mass. A total of 135 postmenopausal women (aged years) with no evidence of moderate or severe periodontal disease were randomized to receive daily oral conjugated estrogen (0.625 mg) alone or in combination with medroxyprogesterone acetate (0.625 and 2.5 mg, respectively) or placebo. Hormone/estrogen replacement therapy significantly increased alveolar bone mass compared with placebo (+1.84% vs %; P =0.04) and increased bone mineral density of the proximal femur, neck, and trochanter, but not the lumbar spine. A two-year randomized, double-blind, placebo-controlled substudy of the Women's Health, Osteoporosis, Progestin, Estrogen trial 16 investigated the effect of lower doses of equine estrogens with medroxyprogesterone acetate on spine and hip BMD, total body bone mineral content (BMC), and biochemical markers of bone turnover in postmenopausal women. At 24 months, women assigned to all of the active treatment groups had significant gains from baseline (P<0.001) in spine and hip BMD and total body BMC. These changes were significantly different from those in the placebo group, in which losses of bone mass in spine and total body were evident over the course of the study (P<0.001). The data from the Postmenopausal Estrogen/Progestin Interventions Trial (PEPI) were re-analysed 17 to address the frequency of bone loss among women using postmenopausal hormone replacement therapy. During the first 12 months, hormone users lost BMD (-3% per year) at the lumbar spine (1,5%) and the total hip (2,3%); during months 12 to 36, only 0.6% and 0,4% of treated women lost spinal and total hip BMD to this degree, respectively. With 95.0% certainty, corresponding to an approximate loss of -2.5% at the spine and hip, 31.3% and 11.7% of placebo-adherent women lost spinal BMD in the first 12 and last 24 months, respectively. Parallel figures for the hip were 32.3% and 7.9%, 4
5 respectively. So, bone loss while taking postmenopausal hormones is rare, and bone loss among untreated women is far from universal. Conclusion The effects on bone mineral density and incidence of fractures are different under use of DMPA and oral MPA. Oral MPA is commonly used in association with estrogens. These estrogens seem to protect against bone loss. More randomized studies with a stronger experimental design (hard clinical outcomes instead of surrogate outcomes; primary analyses instead of sub-analyses) are needed to clarify the effect of MPA therapy on fracture risk among women with and without osteoporosis. Recommendation Based on contemporary evidences, MPA tablets could still be included in the 14 th EDL. Further studies should be carried out to modify this decision or not. References 1. Medroxyprogesterone. Effect on bone mineral density. WHO Pharmaceuticals Newsletter 2004, No. 6. p Morris EP, Rymer J. Menopausal symptoms. Clinicalevidenceonline 2004, Search date March [In 2005, Jan 13] 3. Focan C, Beauduin M, Majois F, Canon J-L, Cusumano G, Focan-Henrard D, Lobelle J-P, for the Adjuvant Breast Cancer Project, Belgium. High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update. Clinical Breast Cancer 2004; 5: Rochon C, Prod'homme M, Laurichesse H, Tauveron I, Balage M, Gourdon F, Baud O, Jacomet C, Jouvency S, Bayle G, Champredon C, Thieblot P, Beytout J, Grizard J. Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients. Reprod Nutr Dev 2003; 43: Irahara M, Uemura H, Yasui T, Kinoshita H, Yamada M, Tezuka M, et al. Efficacy of Every-Other-Day Administration of Conjugated Equine Estrogen and Medroxyprogesterone Acetate on Gonadotropin-Releasing Hormone Agonists Treatment in Women with Endometriosis. Gynecol Obstet Invest 2001; 52: von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mösch R, et al., for the South West German Gynecologic Oncology Group (SWGGOG). Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer a multicentre, open, controlled, prospectively randomised trial. European Journal of Cancer 2002; 38: Chlebowski RT, Wactawski-Wende J,Ritenbaugh C,HubbellFA, Ascensao J, Rodabough RJ, et al., for the Women's Health Initiative Investigators. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. N Engl J Med 2004; 350:
6 8. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001; 98: Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004 May;103(5 Pt 1): Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G, Reid IR. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003; 88: Carr BR, Breslau NA, Peng N, Adams-Huet B, Bradshaw KD, Steinkampf MP.Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebocontrolled, crossover trial. Fertility and Sterility 2003; 80: Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001; 185: Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, Cummings SR. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001; 110: Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al.; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento- Villareal R, et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2002; 162: Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: Greendale GA, Wells B, Marcus R, Barrett-Connor E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000; 160: January
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:
Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationMedroxyprogesterone 10 mg and menopause
Medroxyprogesterone 10 mg and menopause Search Millions of women worldwide, many in their teenage years, have been using the longacting, injectable depot medroxyprogesterone. L acétate de médroxyprogestérone
More informationCryopreservation and transplantation of ovarian tissue exclusively to postpone menopause technically possible but endocrinologically doubtful
Cryopreservation and transplantation of ovarian tissue exclusively to postpone menopause technically possible but endocrinologically doubtful Michael von Wolff, M. D., Petra Stute, M. D. Division of Gynaecological
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationThe Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis
Curr Obstet Gynecol Rep (2012) 1:50 58 DOI 10.1007/s13669-012-0007-6 MANAGEMENT OF MENOPAUSE (K-E HUANG, SECTION EDITOR) The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationSerum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women
Maturitas 50 (2005) 19 29 Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationBenton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
More informationGynecologists are first-line providers for
Update OSTEOPOROSIS A new agent, and new understandings of old drugs, top the year s developments in bone health Steven R. Goldstein, MD Dr. Goldstein is Professor, Department of Obstetrics and Gynecology,
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationSPRMs, androgens and breast cancer
SPRMs, androgens and breast cancer Dr Joëlle Desreux BMS 04/06/2016 WHI : the nuclear explosion Looking for the perfect menopause treatment Hot flushes relieve Osteoporosis prevention Cardio-vascular health
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationHormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]
Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited
More information10/11/2016. Richard J. Santen, MD. Disclosures. Key Question Regarding MHT and Breast Cancer Development. NAMS 2016 Translational Science Symposium
Richard J. Santen, MD NAMS 2016 Translational Science Symposium Risks and Benefits Related to the Breast Disclosures Current Grant Funding: Pfizer Previous Advisory Boards: Pfizer, Teva, Novo-Nordisk,
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More information9/27/2017. Disclosure. Selecting Progestogens: Breast, Cardiovascular, and Cognitive Outcomes. James H Liu, MD. Overview
Disclosure Selecting Progestogens: Breast, Cardiovascular, and Cognitive utcomes James H Liu, MD Arthur H Bill Professor and Chair Departments of Reproductive Biology and bstetrics and Gynecology UH Cleveland
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationHRT: Neue Kombinationen
HRT: Neue Kombinationen 4. Februar 2015 Gyndolomiti Cumulative Hazards of Invasive Breast Cancer WHI Conj. Estrogen + MPA Cumulative Hazards of Invasive Breast Cancer WHI Estrogen only CE+MPA Time, y WHI
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationLong-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
DOI: 10.1111/1471-0528.12598 www.bjog.org Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationHormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive
Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...
More informationApplying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1
Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:
More informationthe cumulative rates of persistence with estrogen replacement therapy, CEE/MPA and tibolone;
Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of climacteric symptoms in postmenopausal women Diaby V, Perreault S, Lachaine J Record Status
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationEveryone knows 1/15/2018. Does Osteopenia Warrant Treatment? Osteoporosis Prevention: Is it Ever Warranted?
/5/8 Wednesday, October, 7 : AM :5 AM Osteoporosis Prevention: Is it Ever Warranted? James A. Simon, MD, CCD, NCMP, IF, FACOG Clinical Professor Department of Ob/Gyn George Washington University Washington,
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationMenopausal hormone therapy includes various forms, Review
Review Annals of Internal Medicine Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationMenopausal Hormone Therapy
V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationHypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement. Hypothalamic amenorrhea NASPAG ACRM 2015
Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement Meredith Loveless, MD Gina Sucato, MD MPH NASPAG ACRM 2015 Hypothalamic amenorrhea Functional hypothalamic amenorrhea Absence
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationHow long should we treat primary osteoporosis?
Earn 3 CPD Points online Current Osteoporosis management With a FOCUS on ideal length of treatment and considerations in the use of menopausal hormone therapy for fracture prevention Dr Tobie De Villiers
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationPhysiology of Menopause
6/4/18 21 Physiology of Menopause Timothy Rowe University of British Columbia 6/4/18 22 I have received consulting fees and honoraria for speaking from Pfizer Canada Inc. I have no other competing or potentially
More information